MTAP and cancer: The PRMT5 (Protein Arginine Methyltransferase 5) inhibitor, EZP015556, was shown to target MTAP (methylthioadenosine phosphorylase)-negative tumors, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors, indicating the importance of personalized approaches for cancer treatment.